To Disclose or Not to Disclose … That is the Question: The DOJ’s FCPA Pilot Program – Insights from Year One and Beyond

This article examines settlement trends before and during the Pilot Program to answer the question of whether or not it is sensible to self-disclose.
Last month, Sandra Moser, the acting chief of the DOJ’s Fraud Section made it clear that the DOJ would be increasing its enforcement efforts of healthcare related companies. Although life science companies have not been immune to Foreign Corrupt Practices Act (“FCPA”) investigations in the past, Moser stated that the DOJ viewed the healthcare industry as ‘one that faces serious compliance and corruption challenges not only in high risk markets overseas but right here at home as well.’ Simply put, life science companies will be under the FCPA microscope more than ever.
To Read the Full Story, Subscribe, Download a Sample Issue, or Sign In

      Related StoriesFalse Claims Act Mid-Year Review: Significant Life Science Settlements, Post-Escobar Developments & Industry Round UpOhio Drug Distribution Verification: America’s Key Battleground State Shakes Up the Pharmaceutical Supply ChainFDA Warns Cipher Over “Misleading” Marketing Materials 

Source: Policy and Medicine - September 22, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs